nicast focuses on biomedical applications like vascular grafts, stent grafts, and coated stents (with or without pharmaceuticals), using its proprietary electrospinning technological platform. nicast's first application, an artificial peripheral vascular graft, is in pre-clinical studies. the graft's mechanical and in vivo (animal study) performance indicates significant advantages over competing products. electrospinning technology enables a generation of artificial implants that are stronger than current products and can be produced in complex shapes and homogeneous structures. the technology significantly reduces obstruction rates compared with competing devices now on the market.